, ECR double aveugle de supériorité, vol.2013
, Commission de la Transparence : rapport d'évaluation des médicaments anticoagulants oraux, HAS, 2016.
Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis, Health Technol Assess, vol.21, issue.9, pp.1-386, 2017. ,
Perception de l'utilisation des anticoagulants oraux directs : enquête auprès des médecins généralistes, 2014. ,
Nouveaux anticoagulants oraux : à qui les prescrivons-nous ? Etude Cacao / phase, p.12 ,
, , 2019.
150 mg gél -Pharmacodynamie, 2019. ,
, Les anticoagulants oraux
, , 2019.
Prise en charge des hémorragies et des gestes invasifs urgents chez les patients recevant un anticoagulant oral et direct anti-IIa (dabigatran), p.22 ,
Oral rivaroxaban for symptomatic venous thromboembolism, N Engl J Med, vol.363, issue.26, pp.2499-510, 2010. ,
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism, N Engl J Med, vol.366, issue.14, pp.1287-97, 2012. ,
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis, Circulation, vol.129, issue.7, pp.764-72, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-01030866
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism, N Engl J Med, vol.369, issue.15, pp.1406-1421, 2013. ,
Oral apixaban for the treatment of acute venous thromboembolism, N Engl J Med, vol.369, issue.9, pp.799-808, 2013. ,
URL : https://hal.archives-ouvertes.fr/hal-00932477
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients, Journal of Thrombosis and Haemostasis, vol.3, issue.4, pp.692-696, 2005. ,
Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials, Blood, vol.124, issue.12, pp.1968-75, 2014. ,
Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis, PLoS ONE, vol.10, issue.12, p.144856, 2015. ,
The epidemiology of venous thromboembolism, J Thromb Thrombolysis, vol.41, issue.1, pp.3-14, 2016. ,
Once-Daily Oral Rivaroxaban Versus Placebo in the Long-Term Prevention of Recurrent Symptomatic Venous Thromboembolism. the Einstein-Extension Study, Blood, vol.114, issue.22, pp.2-2, 2009. ,
Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism, New England Journal of Medicine, vol.368, issue.8, pp.709-727, 2013. ,
URL : https://hal.archives-ouvertes.fr/hal-00935796
Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism, N Engl J Med, vol.30, issue.13, pp.1211-1233, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-02051875
Apixaban for extended treatment of venous thromboembolism, N Engl J Med, vol.368, issue.8, pp.699-708, 201321. ,
URL : https://hal.archives-ouvertes.fr/hal-00771313
Editor's Choice -Efficacy and Safety of the New Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Edoxaban in the Treatment and Secondary Prevention of Venous Thromboembolism: A Systematic Review and Meta-analysis of Phase III Trials, European Journal of Vascular and Endovascular Surgery, vol.48, issue.5, pp.565-75, 2014. ,
Comparison of the Non-VKA Oral Anticoagulants Apixaban, Dabigatran, and Rivaroxaban in the Extended Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis, PLoS ONE, vol.11, issue.8, p.160064, 2016. ,
Epidemiology of cancerassociated venous thrombosis, Blood, vol.122, issue.10, pp.1712-1735, 2013. ,
Apixaban versus Dalteparin for the Treatment of Acute Venous Thromboembolism in Patients with Cancer: The Caravaggio Study, Thromb Haemost, vol.118, issue.9, pp.1668-78, 2018. ,
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism, N Engl J Med, vol.378, issue.7, pp.615-639, 2018. ,
Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial ,
, J Clin Oncol, vol.36, issue.20, pp.2017-2040, 2018.
Direct oral anticoagulant (DOAC) versus lowmolecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis, Thromb Res, vol.173, pp.158-63, 2019. ,
Efficacy and safety of anticoagulant agents in patients with venous thromboembolism and cancer: A network meta-analysis, Thrombosis Research, vol.170, pp.175-80, 2018. ,
Dabigatran versus warfarin in patients with atrial fibrillation, N Engl J Med, vol.361, issue.12, pp.1139-51, 2009. ,
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation, New England Journal of Medicine, vol.365, issue.10, pp.883-91, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-01038111
Apixaban in patients with atrial fibrillation, N Engl J Med, vol.364, issue.9, pp.806-823, 2011. ,
Edoxaban versus Warfarin in Patients with Atrial Fibrillation, New England Journal of Medicine, vol.369, issue.22, pp.2093-104, 2013. ,
URL : https://hal.archives-ouvertes.fr/hal-00934699
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. The Lancet, vol.383, pp.955-62, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-00935589
A systematic review of network meta-analyses among patients with nonvalvular atrial fibrillation: A comparison of efficacy and safety following treatment with direct oral anticoagulants, Int J Cardiol, vol.269, pp.174-81, 2018. ,
,
, Rev Mal Respir, 2019.
,
, CHEST Guideline and Expert Panel Report. Chest, vol.149, issue.2, pp.315-52, 2016.
The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC), Eur Respir J, 2019. ,
ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS, Eur Heart J, vol.37, issue.38, pp.2893-962, 2016. ,
, , 2019.
AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society, J Am Coll Cardiol, vol.74, issue.1, pp.104-136, 2009. ,
Etude descriptive de la Prescription des Anticoagulants Oraux dans des cabinets de Médecine Générale, 2016. ,
Rôle du cardiologue dans la prescription des innovations thérapeutiques par les médecins généralistes de Midi Pyrénées : A propos des anticoagulants oraux directs, 2016. ,
HAS : Commission de la transparence Avis Dabigatran, 2018. ,
Évaluation des pratiques des médecins généralistes sur la prescription des anticoagulants oraux directs (dabigatran pradaxa ® , rivaroxaban xarelto ® et apixaban eliquis ® ) chez les personnes âgées de plus de 75 ans sur le secteur sanitaire palois, 2015. ,
Modalités de prescription des anticoagulants oraux directs en 2015-2016 en Aveyron, 2016. ,
Perception des anticoagulants oraux directs chez les médecins généralistes en Rhône-Alpes: étude qualitative par focus groups auprès de 19 médecins généralistes, 2014. ,
Comparative Effectiveness and Safety of Direct Oral Anticoagulants in Patients with Atrial Fibrillation: A Systematic Review and Meta-Analysis of Observational Studies, Drug Saf, 2019. ,
Real-life Use of Anticoagulants in Venous Thromboembolism With a Focus on Patients With Exclusion Criteria for Direct Oral Anticoagulants, Clinical Pharmacology & Therapeutics, vol.103, issue.4, pp.684-91, 2018. ,
,
, , 2019.
,
, , 2019.